









Markets
/
Stocks
/
nasdaq-dvax
/

Dynavax Technologies Corp

DVAX

15.500USD

+0.010+0.06%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.82BMarket Cap

LossP/E TTM



Dynavax Technologies Corp

15.500

+0.010+0.06%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dynavax Technologies Corp

Currency: USD Updated: 2026-02-06

Key Insights

Dynavax Technologies Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 37 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dynavax Technologies Corp's Score

Industry at a Glance

Industry Ranking

37 / 392

Overall Ranking

141 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Dynavax Technologies Corp Highlights

StrengthsRisks

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -42.61, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 115.83M shares, increasing 0.06% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.65K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

20.500

Target Price

+32.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Dynavax Technologies Corp is 8.89, ranking 23 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 94.88M, representing a year-over-year increase of 17.67%, while its net profit experienced a year-over-year increase of 53.05%.

Score

Industry at a Glance

Previous score

8.89

Change



Financials

8.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.75

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Dynavax Technologies Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Dynavax Technologies Corp is 7.94, ranking 73 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -42.61, which is -501.11% below the recent high of 170.92 and -608.32% above the recent low of -301.83.

Score

Industry at a Glance

Previous score

7.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 37/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Dynavax Technologies Corp is 7.33, ranking 294 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.50, with a high of 31.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

20.500

Target Price

+32.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Dynavax Technologies Corp

DVAX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Dynavax Technologies Corp is 5.63, ranking 305 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.69 and the support level at 15.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.64

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.311

Neutral

RSI(14)

75.996

Buy

STOCH(KDJ)(9,3,3)

25.491

Neutral

ATR(14)

0.059

Low Volatility

CCI(14)

-46.261

Neutral

Williams %R

82.609

Oversold

TRIX(12,20)

0.406

Sell

StochRSI(14)

16.402

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

15.494

Buy

MA10

15.491

Buy

MA20

15.555

Sell

MA50

13.691

Buy

MA100

12.001

Buy

MA200

11.190

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Dynavax Technologies Corp is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 109.38%, representing a quarter-over-quarter decrease of 3.57%. The largest institutional shareholder is The Vanguard, holding a total of 8.01M shares, representing 7.04% of shares outstanding, with 2.48% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Deep Track Capital LP

15.73M

BlackRock Institutional Trust Company, N.A.

14.70M

-6.96%

The Vanguard Group, Inc.

Star Investors

8.08M

-3.89%

State Street Investment Management (US)

6.29M

-1.73%

Millennium Management LLC

4.53M

+180.74%

Dimensional Fund Advisors, L.P.

3.57M

-2.12%

Chicago Capital, LLC

4.31M

-17.58%

Renaissance Technologies LLC

Star Investors

3.14M

+8.73%

Two Sigma Investments, LP

3.01M

-20.67%

Geode Capital Management, L.L.C.

2.53M

-5.89%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dynavax Technologies Corp is 5.01, ranking 59 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.